Simple Smart Seminar
  • Stock
  • Investing
  • Politics
  • Tech News
  • Editor’s Pick
Editor's PickInvesting

No, It’s Not Price Controls When Government Reduces the Prices It Pays for Medicines

by May 12, 2025
May 12, 2025 0 comment

Michael F. Cannon

medicaid, subsidies

UPDATE: The executive order President Trump signed today does in fact attempt to impose price controls on private purchases of prescription drugs. See this blog post for specifics. The substance of this blog post remains true. 


Government should not purchase medicines for civilians. Period. The US Medicare and Medicaid programs illustrate why. Medicare pays significantly higher prices for medicines than other government programs. Medicaid likewise overpays for prescription drugs and has spillover effects that increase drug prices for private purchasers. These programs pay excessive prices partly because Congress largely let the pharmaceutical industry write each program’s drug-pricing rules.

Government should get out of the business of purchasing or subsidizing medicines for civilians. In other words, the price that Medicare and Medicaid should be paying for drugs is $0.00. To the extent that Trump’s executive order moves the prices Medicare pays for medicines closer to the ideal price of $0.00, it is a step in the right direction.

It is not a “price control” when the government reduces the prices Medicare pays for drugs. Price controls are coercive restraints government places on private actors. If Medicare pays less for drugs, by contrast, private actors remain free to buy and sell at whatever prices make them happy.

If Congress fears that lower Medicare prices would lead to insufficient pharmaceutical research, development, and innovation, the way to correct that market failure is to adjust the patent system. Medicare is not a drug-innovation program. Moreover, the patent system is constitutional. Medicare is not.

0 comment
0
FacebookTwitterPinterestEmail
previous post
ICE Agents Routinely Mask Up When Seizing People—That’s Wrong
next post
The Best Five Sectors, #18

You may also like

Is AI a Horse or a Zebra When...

July 28, 2025

The AI Action Plan: Taking AI Innovation Seriously

July 28, 2025

College Student Aid Theft

July 28, 2025

Can the White House Denaturalize Domestic Opponents?

July 25, 2025

An Updated Interview with George Selgin on Free...

July 25, 2025

Inflation Can Increase Capital Gains Tax Rate to...

July 25, 2025

Friday Feature: Edefy, “Pod Schooling Made Simple”

July 25, 2025

Yiwu: China’s Free-Market City

July 25, 2025

Chart Mania – 23 ATR Move in QQQ...

July 25, 2025

Man Admits to Medicaid Fraud—That’s Not the Worst...

July 25, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Chart Mania – 23 ATR Move in QQQ – Metals Lead 2025 – XLV Oversold – XLU Breakout – ITB Moment of Truth

      July 25, 2025
    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

      July 24, 2025
    • Momentum Leaders Are Rotating — Here’s How to Find Them

      July 24, 2025
    • Is META Breaking Out or Breaking Down?

      July 23, 2025
    • A Wild Ride For the History Books: 2025 Mid-Year Recap

      July 23, 2025
    • Tech Taps the Brakes, Homebuilders Hit the Gas: See the Rotation on StockCharts Today

      July 22, 2025
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 simplesmartseminar.com | All Rights Reserved

    Simple Smart Seminar
    • Stock
    • Investing
    • Politics
    • Tech News
    • Editor’s Pick